Jefferies Reiterates Their Buy Rating on Bluebird Bio

By Austin Angelo

In a report issued on August 9, Eun Yang from Jefferies reiterated a Buy rating on Bluebird Bio (NASDAQ: BLUE), with a price target of $88. The company’s shares closed yesterday at $93.95.

According to, Yang is a 4-star analyst with an average return of 3.3% and a 46.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, DBV Technologies SA – American, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Bluebird Bio is Moderate Buy and the average price target is $97.91, representing a 4.2% upside.

In a report issued on August 2, BMO Capital also reiterated a Buy rating on the stock with a $108 price target.

The company has a one year high of $123.75 and a one year low of $37.05. Currently, Bluebird Bio has an average volume of 1M.

Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Eric Sullivan, the CAO of BLUE sold 861 shares for a total of $80,786.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.